Compare TG Therapeutics Inc (TGTX) vs Direxion Daily 20 Year Treasury Bull 3X Shares (TMF) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
TG Therapeutics Inc vs Direxion Daily 20 Year Treasury Bull 3X Shares — how do they compare? TG Therapeutics Inc trades at $49.62 (market cap $7.64B), while Direxion Daily 20 Year Treasury Bull 3X Shares trades at $30.77. The key difference: TG Therapeutics Inc is trading nearer its 52-week high, Direxion Daily 20 Year Treasury Bull 3X Shares nearer its low. Which is the better fit depends on your goals.
| TGTX | TMF | |
|---|---|---|
Market Cap | $7.64B | — |
Sector | Health | Leveraged / Inverse |
52-Week High | $59.06 | $44.14 |
52-Week Low | $26.94 | $30.59 |
Enterprise Value | $7.84B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
TG Therapeutics (TGTX) trades at $49.66, up 1.02% on the day, with a bearish technical signal and recent earnings misses despite strong revenue growth. The company reported Q2 2026 revenue of $240 million and raised full-year BRIUMVI guidance to $950 million, but net income was impacted by manufacturing investments. Valuation ratios show a high P/E of 18.22 and EV/EBITDA of 56.26, while profitability metrics like ROE of 100.28% remain robust.
Outlook is mixed: strong product demand and raised revenue targets support growth, but earnings volatility and a bearish technical trend pose risks. Analyst consensus is bullish with an $63.75 price target, though legal investigations and competitive pressures require monitoring for stock investors.
TMF, the Direxion Daily 20+ Year Treasury Bull 3X ETF, trades at $30.93 with a 0.95% daily gain. Technical indicators show a bearish trend with moving averages and ADX signaling sell conditions, while oscillators remain neutral. The ETF faces significant fundamental challenges with unavailable valuation and profitability metrics, reflecting its leveraged structure that amplifies both gains and losses in long-duration treasuries.
The outlook for TMF remains high-risk due to its daily leverage reset mechanism, making it unsuitable for long-term holdings. While some analysts see potential at bond market lows, the dominant view cautions against current purchases given the substantial erosion of value over time, with $10,000 invested five years ago now worth approximately $1,527 according to 24/7 Wall Street analysis from June 2026.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About TG Therapeutics Inc
TG Therapeutics is a fully integrated biopharmaceutical company focused on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases. Its cornerstone product, BRIUMVI (ublituximab-xiiy), is a glycoengineered monoclonal antibody approved for relapsing forms of multiple sclerosis. The company is currently executing a 'pipeline-in-a-product' strategy, expanding BRIUMVI into new delivery methods and indications while advancing a broader portfolio of autoimmune and oncology candidates.
Read more on TGTX →About Direxion Daily 20 Year Treasury Bull 3X Shares
TMF is a leveraged ETF that seeks to provide 300% (3x) of the daily performance of the ICE U.S. Treasury 20+ Year Bond Index. It is a tactical instrument used by sophisticated traders to capitalize on declining interest rates or to hedge against equity market volatility. Due to its daily reset mechanism and high expense ratio, TMF is structurally designed for short-term speculation rather than long-term buy-and-hold investing.
Read more on TMF →
